Innoveren Scientific (IVRN) 10-K 30 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 26, 2018	Jun. 30, 2017
Document And Entity Information
Entity Registrant Name	Medovex Corp.
Entity Central Index Key	1,591,165
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 11,568,161
Entity Common Stock, Shares Outstanding		21,933,013
Trading Symbol	MDVX
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current Assets
Cash	$ 245,026	$ 892,814
Accounts receivable	157,069
Other receivables	86,888
Inventory	294,714
Prepaid expenses	204,532	364,822
Short-term receivable	150,000
Total Current Assets	1,138,229	1,257,636
Long Term Receivable		150,000
Property and Equipment, net of accumulated depreciation	87,173	97,590
Deposits	2,751	2,751
Total Assets	1,228,153	1,507,977
Current Liabilities
Interest payable	69,222	69,222
Accounts payable	196,171	225,725
Accounts payable to related parties	12,319
Accrued liabilities	64,000	459,800
Notes payable, current portion	132,294	126,086
Short-term note payable, net of debt discount		970,240
Unearned revenue	1,048
Total Current Liabilities	475,054	1,851,073
Long-Term Liabilities
Notes payable, net of current portion	38,990	103,742
Deferred rent	688	1,179
Total Long-Term Liabilities	39,678	104,921
Total Liabilities	514,732	1,955,994
Stockholders' Equity (Deficit)
Preferred stock - $.001 par value: 500,000 shares authorized, 12,740 shares issued and outstanding at December 31,2017, no shares issued issued and outstanding at December 31, 2016	13
Common stock - $.001 par value: 49,500,000 shares authorized, 21,163,013 and 14,855,181 shares issued and outstanding at December 31, 2017 and December 31, 2016, respectively	21,163	14,855
Additional paid-in capital	33,509,648	25,898,054
Accumulated deficit	(32,817,403)	(26,360,926)
Total Stockholders' Equity (Deficit)	713,421	(448,017)
Total Liabilities and Stockholders' Equity (Deficit)	$ 1,228,153	$ 1,507,977

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	12,740	0
Preferred stock, shares outstanding	12,740	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	49,500,000	49,500,000
Common stock, shares issued	21,163,013	14,855,181
Common stock, shares outstanding	21,163,013	14,855,181

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Revenues	$ 207,396
Less: Discounts allowed	(52)
Cost of Goods Sold	(162,837)
Gross Profit	44,507
Operating Expenses
General and administrative	4,721,893	4,872,626
Sales & Marketing	865,377	391,698
Research and development	491,076	1,126,535
Depreciation and amortization	27,100	11,267
Impairment of goodwill		6,455,645
Total Operating Expenses	6,105,446	12,857,771
Operating Loss	(6,060,939)	(12,857,771)
Other Income	957
Other Expenses
Interest expense	395,332	455,304
Total Other Expenses	395,322	455,304
Loss from Continuing Operations	(6,455,314)	(13,313,075)
Discontinued Operations
Loss from discontinued operations	1,163	477,497
Impairment loss		1,584,048
Disposal loss		852,864
Total Loss from Discontinued Operations	(1,163)	(2,914,409)
Net Loss	$ (6,456,477)	$ (16,227,484)
Loss per share - Basic and Diluted
Continued Operations	$ (0.34)	$ (1)
Discontinued Operations		(0.22)
Net Loss per share	$ (0.34)	$ (1.22)
Weighted average outstanding shares used to compute basic and diluted net loss per share	19,142,795	13,250,789

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Due From Stockholder [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Beginning Balance at Dec. 31, 2015	$ 11,256		$ (20,000)	$ 20,164,911	$ (10,133,442)	$ 10,022,725
Beginning Balance, Shares at Dec. 31, 2015	11,256,175
Conversion of promissory note on January 25, 2016	$ 552			1,071,961		1,072,513
Conversion of promissory note on January 25, 2016, Shares	552,041
Warrant price modification on January 25, 2016				18,050		18,050
Warrant price modification on February 16, 2016				7,670		7,670
Receivable portion of note of convertible debt			20,000			20,000
Issuance of common stock pursuant to a private placement completed in April 2016	$ 1,212			800,435		801,647
Issuance of common stock pursuant to a private placement completed in April 2016, Shares	1,211,703
Issuance of warrants pursuant to a private placement completed in April 2016				374,623		374,623
Issuance of common stock in exchange for consulting services in April 2016	$ 38			47,962		48,000
Issuance of common stock in exchange for consulting services in April 2016, Shares	37,500
Issuance of common stock pursuant to a private placement completed in August 2016	$ 1,083			975,526		976,609
Issuance of common stock pursuant to a private placement completed in August 2016, Shares	1,083,333
Issuance of warrants pursuant to a private placement completed in August 2016				323,391		323,391
Issuance of common stock in exchange for consulting services in August 2016	$ 60			76,740		76,800
Issuance of common stock in exchange for consulting services in August 2016, Shares	60,000
Issuance of warrants pursuant to a term loan completed in September 2016				135,971		135,971
Issuance of common stock in exchange for consulting services in September 2016	$ 83			124,417		124,500
Issuance of common stock in exchange for consulting services in September 2016, Shares	83,000
Issuance of common stock pursuant to a private placement completed in December 2016	$ 571			999,429		1,000,000
Issuance of common stock pursuant to a private placement completed in December 2016, Shares	571,429
Stock based compensation				776,968		776,968
Net loss					(16,227,484)	(16,227,484)
Ending Balance, Amount at Dec. 31, 2016	$ 14,855			25,898,054	(26,360,926)	(448,017)
Ending Balance, Shares at Dec. 31, 2016	14,855,181
Issuance of common stock in exchange for BOD fees in January 2017	$ 174			239,826		240,000
Issuance of common stock in exchange for BOD fees in January 2017, Shares	173,912
Issuance of common stock pursuant to a private placement complete in February 2017	$ 1,632			1,207,032		1,208,664
Issuance of common stock pursuant to a private placement complete in February 2017, Shares	1,631,730
Issuance of preferred stock pursuant to a private placement completed in February 2017		$ 13		943,673		943,686
Issuance of preferred stock pursuant to a private placement completed in February 2017, Shares		12,740
Issuance of warrants pursuant to a private placement completed in February 2017				465,709		465,709
Issuance of common stock pursuant to the conversion of a short term note in February 2017	$ 166			145,753		$ 145,919
Issuance of common stock pursuant to the conversion of a short term note in February 2017, Shares	165,865					200,000
Issuance of preferred stock pursuant to the conversion of a short term note in February 2017		$ 9		826,865		$ 826,874
Issuance of preferred stock pursuant to the conversion of a short term note in February 2017, Shares		9,399
Issuance of warrants pursuant to the conversion of a short term note in February 2017				177,207		177,207
Issuance of common stock pursuant to warrant cancellations in February 2017	$ 200			207,800		208,000
Issuance of common stock pursuant to warrant cancellations in February 2017, Shares	200,000
Issuance of common stock pursuant to preferred stock conversion in March 2017	$ 415	$ (4)		(411)
Issuance of common stock pursuant to preferred stock conversion in March 2017, Shares	414,663	(4,147)
Issuance of common stock pursuant to preferred stock conversion in April 2017	$ 525	$ (5)		(520)
Issuance of common stock pursuant to preferred stock conversion in April 2017, Shares	525,240	(5,252)
Issuance of common stock pursuant to a private placement completed in July 2017	$ 2,956			2,019,670		2,022,626
Issuance of common stock pursuant to a private placement completed in July 2017, Shares	2,956,043
Issuance of warrants pursuant to a private placement completed in July 2017				446,561		446,561
Issuance of common stock in exchange for BOD Fees in October 2017	$ 115			134,885		135,000
Issuance of common stock in exchange for BOD Fees in October 2017, Shares	115,389
Issuance of common stock in exchange for consulting services in October 2017	$ 75			80,925		81,000
Issuance of common stock in exchange for consulting services in October 2017, Shares	74,990
Issuance of common stock in exchange for consulting services in December 2017	$ 50			33,450		33,500
Issuance of common stock in exchange for consulting services in December 2017, Shares	50,000
Stock based compensation				683,169		683,169
Net loss					(6,456,477)	(6,456,477)
Ending Balance, Amount at Dec. 31, 2017	$ 21,163	$ 13		$ 33,509,648	$ (32,817,403)	$ 713,421
Ending Balance, Shares at Dec. 31, 2017	21,163,013	12,740

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash Flows from Operating Activities
Net loss	$ (6,456,477)	$ (16,227,484)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	27,100	11,396
Amortization of intangible assets		189,522
Amortization of debt discount	31,773	357,297
Debt conversion expense	355,985	68,694
Intangible asset impairment loss		1,584,048
Goodwill impairment loss		6,455,645
Disposal loss		(852,864)
Stock based compensation	683,169	776,968
Straight-line rent adjustment	(491)	688
Common stock issued for consulting services	114,500	249,300
Non-cash directors fees		20,000
Adjustment of fair value of warrant modification		25,720
Changes in operating assets and liabilities, net of effects of acquisition and disposition:
Accounts receivable	(157,069)	33,045
Other receivables	(86,888)
Prepaid expenses	229,632	(128,400)
Inventory	(294,714)
Unearned revenue	1,048
Accounts payable	(29,554)	(52,584)
Interest payable		(3,670)
Accounts payable to related parties	12,319
Accrued liabilities	(20,800)	359,483
Net Cash Used in Operating Activities	(5,590,467)	(5,427,468)
Cash Flows from Investing Activities
Proceeds from disposition of, net assets of Streamline Inc.		500,000
Expenditures for property and equipment	(16,682)	(85,133)
Net Cash (Used in) Provided by Investing Activities	(16,682)	414,867
Cash Flows from Financing Activities
Principal payments under note payable obligation	(127,885)	(136,022)
Proceeds from issuance of common stock, net of offering costs	3,838,671	2,778,256
Proceeds from issuance of warrants, net of offering costs	1,248,575	833,985
Proceeds from issuance of short term debt		859,029
Net Cash Provided by Financing Activities	4,959,361	4,335,248
Net Decrease in Cash	(647,788)	(677,353)
Cash - Beginning of period	892,814	1,570,167
Cash - End of period	245,026	892,814
Cash paid for interest	7,161	11,469
Non-cash investing and financing activities
Finance agreement for insurance policy	69,343	66,582
Conversion of note and accrued interest to common stock and preferred stock	826,874	1,072,513
Conversion of short-term loan to common stock	145,919
Issuance of warrants for conversion of note	177,207
Issuance of common stock for consulting services	114,500	249,300
Common stock issued for board fees	375,000
Issuance of common stock for preferred stock conversion	931
Issuance of common stock warrants for placement agent fees	153,688
Repayment of due from stockholder through forgone director fees		20,000
Note receivable from disposition of Streamline		$ 150,000

Organization

Organization	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Note 1 - Organization Description of Business MedoveX Corp. (the “Company” or “MedoveX”), was incorporated in Nevada on July 30, 2013 as SpineZ Corp. (“SpineZ”) and changed its name to MedoveX Corp. on March 20, 2014. MedoveX is the parent company of Debride Inc. (“Debride”), which was incorporated under the laws of the State of Florida on October 1, 2012. The Company is in the business of designing and marketing proprietary medical devices for commercial use in the United States and Europe. The Company received CE marking in June 2017 for the DenerveX System and it is now commercially available throughout the European Union and several other countries that accept CE marking. The Company’s first sale of the DenerveX System occurred in July 2017. The Company plans to seek approval for the DenerveX System from the Food & Drug Administration (“FDA”) in the United States. In May 2016, the Board of Directors authorized management to seek buyers for Streamline, Inc., the Company’s wholly owned subsidiary acquired in March 2015. In December 2016, the Company entered into a definitive asset purchase agreement pursuant to which the Company agreed to sell all Streamline assets upon consummation of the divestiture (the “Closing”). The Closing occurred immediately following the execution of the asset purchase agreement on December 7, 2016. (See Note 10)

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies Basis of Presentation And Principles of Consolidation The accompanying consolidated financial statements include the accounts of MedoveX Corp., its wholly-owned subsidiary, Debride, as well as its wholly owned subsidiary, Streamline Inc. (“Streamline”). All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates In preparing the financial statements, generally accepted accounting principles in the United States (“U.S. GAAP”) requires disclosure regarding estimates and assumptions used by management that affect the amounts reported in financial statements and accompanying notes. Actual results could differ from those estimates. Cash The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s cash balances at December 31, 2017 and 2016 consists of funds deposited in checking accounts with commercial banks. Accounts Receivable, Sales Returns, Discounts and Allowances Accounts receivable primarily represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized. The allowance is estimated for trade accounts receivable based on the expected collectability of accounts receivable after considering the Company’s historical collection experience and the length of time an account is outstanding. The adequacy of this allowance is reviewed each reporting period and adjusted as necessary. As the Company only commenced sales in July 2017, all outstanding trade receivables were deemed collectable, thus, no allowance for doubtful accounts was recorded at December 31, 2017 and 2016. Other Receivables Other receivables include input and importation value added tax (VAT) paid by the Company for conducting business in the European Union (“EU”) and for importing goods from outside the EU. Inventory Inventories consist of only finished goods and are valued at the lower of cost or net realizable value, using the first-in, first-out (FIFO) method. Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to five years. Repairs and maintenance are expensed as incurred. Improvements and betterments, which extend the lives of the assets, are capitalized. Leases The Company recognizes rent expense on a straight-line basis over the term of the lease. The lease term commences on the date the Company takes possession of or controls the physical use of the property. Deferred rent is included in non-current liabilities on the balance sheet. Revenue Recognition The Company has elected to early adopt Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers. Under ASC 606, the Company applies a new 5-step revenue recognition process as promulgated, the core principle of which necessitates companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. Identify the contract with the customer Medovex has two types of customers: distributors, and individual hospitals and practitioners. Distributors: We currently have distribution agreements with distributors located in Italy, Austria, Colombia, Scandinavia, Brazil, Israel, Australia, Turkey, Spain, Switzerland, Chile, Taiwan, Poland, Slovakia, the Czech Republic and the United Kingdom. For each distributor, a standardized distribution agreement is executed and is the definitive contract between the Company and the customer. Each distribution agreement details the pricing, order placement, stocking requirements, terms of payment, and shipping terms under which the DenerveX System will be shipped to the distributor. The distributor places orders for additional product, but all these orders are subject to the terms of the Distribution Agreement. Direct Customers: In Germany, all our customers are direct hospitals and individual practitioners. Sales in Germany are solicited by and placed with third party contractors on behalf of Medovex. Medovex has sales agreements with each third party sales representative selling the DenerveX System. Each sales agreement details the price at which the DenerveX System must be sold to the customer. A purchase order from the customer is required before the Company will ship product to the customer. This purchase order contains all the terms and conditions of the sale and is considered the definitive contract for this type of sale. Identify the performance obligation in the contract Our stocking distributors, who sell the DenerveX System to their customers or sub-distributors, contractually take title to the products and assume all risks of ownership at the time of shipment. The Company has no further obligations once the product is shipped. Our stocking distributors are obligated to pay us the contractually agreed upon invoice price within specified terms regardless of when, if ever, they sell the products. Since no right of return exists, the product is not considered consigned inventory. For direct sales to hospitals and practitioners in Germany, the obligation is met when the product is shipped. Our direct customers do not have any contractual rights of return or exchange other than for defective product or shipping error. Determine the transaction price DenerveX Kit: The DenerveX kit consists of one (1) Denervex handheld device, one (1) K-Wire, one (1) dilator, one (1) tissue stabilizer, (1) one portal tube and one (1) portal driver. The product is marketed as a disposable, single-use kit which includes all of the components packaged together. The transaction price for the DenerveX Kit is specifically outlined in the standardized distribution agreements for all distributors at a price of $492.50 per kit (each). The standardized distribution agreements also contain provisions for the purchase of demo-units at a transaction price of $246.25 per kit (each). The sales transaction price for one (1) DenerveX Kit is stated in US dollars for all distribution customers. The transaction price for the DenerveX Kit is specifically outlined in the standardized sales rep agreements for all sales contractors at a price of €1,100 per kit (each). The sales price for one (1) DenerveX Kit is stated in euros for all German sales. Pro-40 Generators: The DenerveX device requires a custom generator for power and cannot be used for any other purpose. For each initial order of the DenerveX Kit, a generator is provided to each customer at no charge. The Company does not recognize any revenue for the no-charge generator units. The units are removed from inventory and recognized as a cost of sales at the time of shipment. Customers may order demo generators, however, the Company charges for these units. The transaction price for the demo generators is specifically outlined in the standardized distribution agreement for all distributors at a price of $2,500 per unit. Allocate the transaction price In the Company’s case, 100% of the transaction price is recorded as revenue. Recognize revenue when or as the entity satisfies a performance obligation Revenue recognition occurs at the time product is shipped, FOB shipping, to all customers from the third-party distribution warehouse located in Berlin, Germany. For Medovex, this is considered the point at which the customer gains control of the Denervex device and there are no remaining material performance obligations. If something abnormal were to happen to the product in transit, the matter would be handles with the carrier, however, the sale would remain intact. Research and Development Research and development costs are expensed as incurred. Advertising The Company expenses all sales and marketing costs as incurred. For the years ended December 31, 2017 and 2016, advertising costs were approximately $332,000 and $224,000, respectively. Translation of Foreign Currencies The Company’s revenues and expenses transacted in foreign currencies are translated as they occur at exchange rates in effect at the time of each transaction. Realized gains and losses on foreign currency transactions are recorded as a component of other income or expense, net on the Company’s consolidated statements of operations. As the Company commenced sales of the DenerveX System in July 2017, the Company recorded an immaterial amount in foreign currency exchange for the year ended December 31, 2017. Assets and liabilities of the Company denominated in foreign currencies are translated at the exchange rate in effect as of the balance sheet date and are recorded as a separate component of accumulated other comprehensive income or loss in the shareholders’ equity section of the Company’s consolidated balance sheet. The Company recorded an immaterial amount in unrealized foreign currency translation as of December 31, 2017, as such, we did not present as a separate component of accumulated other comprehensive income in the shareholders’ equity section of the Company’s consolidated balance sheet. Income Taxes The Company uses the liability method of accounting for income taxes, which requires recognition of temporary differences between financial statement and income tax bases of assets and liabilities, measured by enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets when necessary. Stock-Based Compensation The Company maintains a stock option incentive plan and accounts for stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation Loss per Share Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti- dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share: 7,194,215 warrants and 1,314,059 common stock options outstanding were considered anti-dilutive and excluded for the years presented. Discontinued Operations As more fully described in Note 10, in May 2016, management was authorized to locate a buyer for Streamline Inc., the Company’s wholly owned subsidiary acquired in March 2015, by the Board of Directors. Streamline’s results of operations have been classified as discontinued operations for all periods presented. Fair Value Measurements We measure certain non-financial assets at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group; and applying accounting for business combinations. We use the fair value measurement framework to value these assets and report the fair values in the periods in which they are recorded or written down. The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels. These levels from highest to lowest priority are as follows: ● Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities; ● Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data; and ● Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available. The determination of fair value and the assessment of a measurement’s placement within the hierarchy requires judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. We may also engage external advisors to assist us in determining fair value, as appropriate. Although we believe that the recorded fair value of our financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values. Goodwill And Impairment of Long-Lived Assets Goodwill is the excess of the purchase price over the fair value of net assets of acquired businesses. Goodwill is tested for impairment annually or whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The test for impairment requires us to make several estimates about fair value. Our estimates associated with the goodwill impairment test are considered critical due to the amount of goodwill recorded on our consolidated balance sheets and the judgment required in determining fair value. Other intangible assets include trademarks and purchased technology. Intangible assets with a definite life are amortized on a straight-line basis, as appropriate, with estimated useful lives ranging from five to seven years, and are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. Definite-lived intangible assets are tested for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consist solely of cash. At times throughout the year, the Company may maintain certain US bank account balances in excess of FDIC insured limits. The Company may also maintain German bank account balances in excess of Germany’s deposit guarantee regulations within the framework of the German Banks’ Compensation Scheme. At December 31, 2017, the Company did not have cash deposits that exceeded federally insured deposit limits in the US or Germany. At December 31, 2016, the Company had only US cash deposits that exceeded federally insured deposit limits. The Company believes that its funds are deposited in high credit quality financial institutions. The Company has not experienced any losses in such accounts to date and believes it is not exposed to any significant credit risk associated with its cash deposits. Recently Issued Accounting Pronouncements The Company considers the applicability and impact of all ASUs issued, both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company adopted the amendments of ASU 2014-09 effective quarter ended September 30, 2017. The adoption of this standard did not have a material impact on our consolidated financial statements. In July 2015, the FASB issued ASU 2015-11, “Inventory (Topic 330),” which requires inventory measured using any method other than last-in, first-out or the retail inventory method to be subsequently measured at the lower of cost or net realizable value, rather than the lower of cost or market. ASU No. 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those years. The Company adopted the amendments of ASU 2015-11 effective January 1, 2017. The adoption of this standard did not have a material impact on our consolidated financial statements. In November 2015, FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory	Note 3 – Inventory Inventories consist only of finished goods and are valued at the lower of cost or net realizable value, using the first-in, first-out (FIFO) method. Inventories consisted of the following items as of December 31, 2017, and December 31, 2016: December 31, 2017 December 31, 2016 Split Return Electrodes $ 1,868 $ — Denervex device 111,596 — Pro-40 generator 181,250 — Total $ 294,714 $ —

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 4 - Property and Equipment Property and equipment consists of the following: Useful Life December 31, 2017 December 31, 2016 Furniture and fixtures 5 years $ 67,777 $ 65,987 Computers and software 3 years 31,738 19,928 Leasehold improvements 5 years 35,676 32,593 135,191 118,508 Less accumulated depreciation (48,018 ) (20,918 ) Total $ 87,173 $ 97,590 Depreciation and amortization expense, excluding depreciation and amortization from Streamline, Inc., amounted to $27,100 for the year ended December 31, 2017 and $11,267 for the year ended December 31, 2016.

Patent Assignment and Contribut

Patent Assignment and Contribution Agreements	12 Months Ended
	Dec. 31, 2017
Patent Assignment And Contribution Agreements
Patent Assignment and Contribution Agreements	Note 5 – Patent Assignment and Contribution Agreements On February 1, 2013, the Company issued 750,108 shares of common stock to Scott Haufe, M.D. (“Dr. Haufe”) pursuant to the terms of a Contribution and Royalty Agreement dated January 31, 2013 between the Company and Dr. Haufe. This agreement provides for the Company to pay Dr. Haufe royalties equal to 1% of revenues earned from sales of any and all products derived from the use of the DenerveX technology. Royalties are payable to Dr. Haufe within 30 days after the close of each calendar quarter based on actual cash collected from sales of applicable products. The royalty period expires on September 6, 2030. The Company also executed a co-development agreement for the DenerveX technology with royalty provisions with James R. Andrews, M.D., as more fully described in Note 12. During 2017, the Company incurred an aggregate of approximately $1,600 in expenses under both the royalty and co-development agreements, of which approximately $1,000 was included in accounts payable at December 31, 2017. No royalties were paid in 2016.

Equity Transactions

Equity Transactions	12 Months Ended
	Dec. 31, 2017
Nonmonetary Transactions [Abstract]
Equity Transactions	Note 6 - Equity Transactions Private Placements On February 9, 2017, the Company entered into a Unit Purchase Agreement with selected accredited investors whereby the Company had the right to sell in a private placement a minimum of $3,000,000 and up to a maximum of $5,000,000 of units. Each Unit had a purchase price of $100,000 and consisted of (i) 96,154 shares of the Company’s common stock, par value $0.001 per share at a purchase price of $1.04 per share, and (ii) a warrant to purchase 48,077 shares of common stock. Each warrant has an initial exercise price of $1.50 per share and is exercisable for a period of five (5) years from the date of issuance. Investors had the option to request shares of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”) in lieu of common stock, on a basis of one share of preferred stock for every one hundred shares of common stock. The offering resulted in gross proceeds of $3,022,000 and resulted in the issuance of an aggregate of 1,631,730 shares of common stock, 12,740 shares of Series A Preferred Stock and warrants to purchase 2,005,761 shares of common stock. The placement agent collected an aggregate of approximately $350,000 in fees related to the offering and warrants to purchase an aggregate of 405,577 shares of common stock at a price of $1.50 per share. Each share of Series A Preferred Stock may be converted into shares of fully paid and non-assessable shares of common stock at a rate of one hundred shares of the Company’s common stock for every share of Series A Preferred Stock. On July 14, 2017, the Company entered into a Securities Purchase Agreement with selected accredited investors whereby the Company sold an aggregate of 2,956,043 shares of common stock and 1,478,022 warrants to purchase common stock. The Offering resulted in $2,690,686 in gross proceeds to the Company. The placement agent collected $188,000 in total fees related to the offering. The common stock shares were sold at $0.91 per share which was the closing price of the Company’s common stock on July 13, 2017, the day prior to the agreement. Each warrant has an exercise price of $1.15 and is exercisable for a period of five years commencing six months from the date of issuance. Debt Conversion On February 9, 2017, the Company’s $1,150,000 short-term note payable was converted into an aggregate of 165,865 shares of common stock and 9,399 shares of Series A Preferred Stock, eliminating the Company’s debt obligation. The debt was converted into shares at $1.04 per share, which was the offering price of the Company’s stock in the February private placement. Each share of Series A Preferred Stock may be converted into shares of fully paid and non-assessable shares of common stock at a rate of one hundred shares of the Company’s common stock for every share of Series A Preferred Stock. As consideration for converting the debt, the noteholders’ agreed to receive common stock in lieu of the 200,000 warrants to purchase common stock that were issued in conjunction with the short-term loan. As a result, the 200,000 warrants were cancelled, and the Company issued to the noteholders’ an aggregate of 200,000 shares of common stock. The closing price of the Company’s stock on February 9, 2017, the day the shares were issued, was $1.04 per share. The fair value of the common stock issued was approximately $208,000. preferred Stock Conversion On March 28, 2017, 4,147 shares of Series A Preferred Stock were converted into an aggregate of 414,663 restricted shares of authorized common stock, par value $0.001 per share. On April 21, 2017, 5,252 shares of Series A Preferred Stock were converted into an aggregate of 525,240 restricted shares of authorized common stock, par value $0.001 per share. Stock-Based Compensation Plan 2013 Stock Option Incentive Plan On October 14, 2013, shareholders approved the MedoveX Corp. 2013 Stock Incentive Plan (the “Plan”). Under the Plan, the Company may grant incentive stock options to employees and non-statutory stock options to employees, consultants, and directors for up to 1,150,000 shares of common stock. On November 10, 2016, shareholders approved a 500,000 share increase in the number of shares available for issuance under the Plan, from 1,150,000 to 1,650,000 shares. On October 28, 2017, shareholders approved a 1,000,000 share increase in the number of shares available for issuance under the Plan, from 1,650,000 to 2,650,000 shares. The stock options are exercisable at a price equal to the market value on the date of the grant. The Plan gives full authority for granting options, determining the type of options granted, and determining the fair market value of the options to the Plan Administrator. The Company has the right, but not obligation, to repurchase any shares obtained through exercise of an option from terminated Plan participants. The Company has 90 days from the date of termination to exercise it’s repurchase right. The Company must pay the Fair Market Value (“FMV”) of the shares if the termination was for any reason other than for cause, or the option price (if less than FMV of the shares) if the termination is for cause. The FMV is determined by the Plan Administrator on the date of termination. During 2017, the Company granted options to purchase 189,159 shares of common stock to certain employees. The options vest as follows: 25% on the date of grant and 25% on each of the next three anniversaries. The options granted were at the market value of the common stock on the date of the grant. We utilize the Black-Scholes valuation method to recognize compensation expense over the vesting period. The expected life represents the period that our stock-based compensation awards are expected to be outstanding. We use a simplified method provided in Securities and Exchange Commission release, Staff Accounting Bulletin No. 110, No dividend payouts were assumed as we have not historically paid, and do not anticipate paying, dividends in the foreseeable future. The risk-free rate of return reflects the weighted average interest rate offered for US treasury rates over the expected term of the options. The significant assumptions used to estimate the fair value of the equity awards granted are; Grant date February 3 March 28 Fair value of options granted $ 0.5775 $ 0.6856 Expected term (years) 6 6 Risk-free interest rate 2.10 % 2.11 % Volatility 52.31 % 51.86 % Dividend yield None None For the years ended December 31, 2017 and 2016, the Company recognized approximately $486,000 and $777,000, respectively, as compensation expense with respect to stock options. A summary of the Company’s share-based compensation activity and related information is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Term (Years) Outstanding at 12/31/2015 380,000 $ 3.95 9.1 Granted 744,900 $ 1.24 9.52 Exercised — — — Cancelled — — — Outstanding at 12/31/2016 1,124,900 $ 2.15 9.0 Granted 189,159 $ 1.17 9.10 Exercised — — — Cancelled — — — Outstanding at 12/31/2017 1,314,059 $ 2.01 8.19 Exercisable at 12/31/2017 954,740 $ 2.08 8.13 As of December 31, 2017, there were 359,319 shares of time-based, non-vested stock. Unrecognized compensation cost amounts to approximately $184,000 as of December 31, 2017 and will be recognized as an expense on a straight-line basis over a remaining weighted average service period of 1.73 years. The fair value of vested share-based compensation at December 31, 2017 and 2016 was approximately $544,000 and $697,000, respectively. Common stock issuance In November 2016, the Board authorized the issuance of shares of common stock to all Board members, both current and former, in an amount equivalent to $240,000, representing their accrued but unpaid directors’ fees as of December 31, 2016. In January 2017, the Company issued an aggregate of 173,912 shares at $1.38 per share, which was the average closing price of the Company’s stock during 2016, to fulfill this obligation. The closing price of the Company’s stock on January 17, 2017, the day the shares were issued, was $1.16 per share. In August 2017, the Board authorized the issuance of shares of common stock to all Board members, both current and former, in an amount equivalent to $135,000, representing their accrued but unpaid directors’ fees as of September 30, 2017. In October 2017, the Company issued an aggregate of 115,389 shares at $1.17 per share, which was the average closing price of the Company’s stock through September 30, 2017, to fulfill this obligation. The closing price of the Company’s stock on October 30, 2017, the day the shares were issued, was $1.09 per share. In August 2017, the Board approved an aggregate stock grant of 300,000 restricted common shares from the 2013 Stock Option Plan. Of the 300,000 shares granted, 175,000 of the shares are to be issued to the Company’s investor relations consultant as follows; 25% on August 17, 2017, the date of grant, 40% 4 months from the date of grant, and 35% 1 year from the date of grant. The Company recognized approximately $81,000 as compensation expense with respect to the stock grant for the year ended December 31, 2017. The remaining 125,000 shares, of the 300,000 shares granted, are to be issued to a member of the Company’s Board of Directors as follows; 25% on August 17, 2017, the date of grant, 25% in 1 year from the date of grant and 50% 2 years from the date of grant. The Company recognized approximately $34,000 as compensation expense with respect to the stock grant for the year ended December 31, 2017.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments	Note 7 – Commitments Operating Leases Office Space The Company pays TAG Aviation, a company owned by its Chief Executive Officer, Jarrett Gorlin (“Mr. Gorlin”) for office space that is currently being used as the Company’s principal business location plus utilities (see “Related Party Transactions”) on a monthly basis. Base rental payments under this arrangement are $2,147 per month. Rent expense and utilities cost paid to TAG Aviation amounted to approximately $34,600 and $30,400 for the years ended December 31, 2017 and 2016, respectively. On July 8, 2015, the Company entered into a 3 year lease agreement for a commercial building which commenced on August 1, 2015. Total lease expense for the year ended December 31, 2017 and 2016 was approximately $35,000 and $34,000, respectively, related to this lease. Future minimum lease payments under this rental agreement are approximately as follows: For the year ended December 31, 2018 21,000 $ 21,000 Equipment The Company entered into a non-cancelable 36-month operating lease agreement for equipment on April 22, 2015. The agreement is renewable at the end of the term and requires the Company to maintain comprehensive liability insurance. Total lease expense for the years ended December 31, 2017 and 2016 was approximately $2,600. Future minimum lease payments under this operating lease agreement are approximately as follows: For the year ended : December 31, 2018 800 $ 800 Consulting Agreements In January 2017, the consulting agreement with one of the Company’s founding stockholders to provide business development consulting services was modified from $5,000 per month to $10,000 per month and initially extended through January 2018, however, was modified and terminated effective October 31, 2017. The Company paid $95,000 for the year ended December 31, 2017 under the agreement. The Company paid $55,000 for the year ended December 31, 2016 under the agreement. In July 2017, the Company modified the consulting agreement with the sales, marketing, and distribution consultant in Latin America. The agreement to provide consulting services was modified from $5,000 per month to $7,000 per month and extended through December 31, 2017. The Company paid $66,000 and $10,000, respectively, for the years ended December 31, 2017 and 2016 under this agreement. On August 23, 2017, the Company retained a consulting firm to provide advisory services specific to matters with respect to potential mergers and acquisitions over a nine-month period at a fee of $75,000. The fee is payable in quarterly installments of $25,000 beginning at the start of the advisory period and every three months thereafter. The engagement was originally set to terminate on May 10, 2018, however was terminated early effective December 31, 2017. The Company paid $25,000 in 2017 under the agreement. The Company has consulting agreements with three sales, marketing, and distribution consultants in Europe who provide consulting services for aggregate compensation amounting to approximately €27,500 (approximately $33,000) per month. The consulting agreements, while subject to modifications, commenced at separate dates and will also terminate at separate dates through April 30, 2019. The Company paid approximately $238,000 and $85,000, respectively, for the years ended December 31, 2017 and 2016. Employment Agreements The Company entered into Employment Agreements with each of its five executive officers for aggregate compensation amounting to approximately $1,064,000 and $984,000, per annum, plus customary benefits for the years ended December 31, 2017 and 2016, respectively. These employment agreements, having commenced at separate dates, are for terms of three years which began in October 2013 and ends in January 2018. The agreements provide for the Company to pay six months of severance in the event of (i) the Company’s termination of an executive’s employment without cause, (ii) the resignation by an executive for good reason, (iii) a change in control of the Company, (iv) a material reduction in an executive’s duties, or (v) a requirement that an executive move their primary work location more than 50 miles. Co-Development Agreement In September 2013, the Company executed a Co-Development Agreement with James R. Andrews, M.D. (“Dr. Andrews”) to further evaluate, test and advise on the development of products incorporating the use of the patented technology. In exchange for these services the Company is obligated to pay Dr. Andrews a royalty of 2% of revenues earned from applicable product sales over a period of 5 years. If Dr. Andrews is listed as inventor of any Improvement Patent on the DenerveX device during the 5-year term, he would continue to receive a 1% royalty after the 2% royalty expires for the duration of the effectiveness of the Improvement Patent. See Note 5. Generator development agreement The Company is obligated to reimburse Bovie up to $295,000 for the development of the Pro-40 electrocautery generator. For the year ended December 31, 2017 and 2016, the Company paid approximately $33,200 and $102,400, respectively, under this agreement. Through December 31, 2017, we have paid approximately $422,000 to Bovie for production services. The original $295,000 agreement was a base number along the pathway of development. Additional requirements were incurred as the research and development process progressed and as a result certain prices increased and additional costs were incurred to further customize the DenerveX System. Distribution center and logistic services agreement The Company has a non-exclusive distribution center agreement through June 2019 with a logistics service provider in Berlin, Germany, pursuant to which they manage and coordinate the DenerveX System products which the Company exports to the EU. The Company pays a fixed monthly fee of €2,900 (approximately $3,500) for all accounting, customs declarations and office support, and a variable monthly fee ranging from €1,900 to €6,900 (approximately $2,300 to $8,300), based on volume of shipments, for logistics, warehousing and customer support services. Total expenses paid under the distribution center and logistics agreement was approximately $75,700 for the year ended December 31, 2017.

Short Term Liabilities

Short Term Liabilities	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Short Term Liabilities	Note 8 – Short Term Liabilities Finance Agreement The Company entered into a commercial insurance premium finance and security agreement in December 2017. The agreement finances the Company’s annual D&O insurance premium. Payments are due in quarterly installments of approximately $24,000 and carry an annual percentage interest rate of 5.98%. The Company had an outstanding premium balance of approximately $68,000 at December 31, 2017 related to the agreement, which is included in notes payable, current portion in the consolidated balance sheets. Promissory Notes In conjunction with the consummation of the Streamline acquisition in March 2015, the Company assumed two promissory notes for approximately $135,000 and $125,000 payable to the Bank of North Dakota New Venture Capital Program and North Dakota Development Fund, both outside non-related parties. Assumption of the liabilities was not included as part of the asset purchase agreement that was executed in December 2016. Thus, the Company retained the promissory notes upon consummation of the divestiture. Payments on both of the notes are due in aggregate monthly installments of approximately $5,700 and carry an interest rate of 5%. Both of the notes have a maturity date of August 1, 2019. The promissory notes had outstanding balances of approximately $104,000 and $165,000 at December 31, 2017 and December 31, 2016, respectively. Expected future payments related to the promissory notes as of December 31, 2017, are approximately as follows: For the year ended 2018 64,000 2019 45,000 $ 109,000 The Company paid interest expense related to the promissory notes for the year ended December 31, 2017 and 2016 in the amount of approximately $7,000 and $10,000, respectively. The Company had unpaid accrued interest in the amount of approximately $69,000 at December 31, 2017 and 2016 related to the promissory notes. Short Term Note Payable On September 13, 2016, the Board of Directors approved a resolution authorizing the Company to obtain a secured nine-month term loan for the principal amount of $1,150,000. In connection therewith, on September 16, 2016, the Company entered into a Unit Purchase Agreement with selected accredited investors whereby the Company had the right to sell units in a private placement to secure the loan. On February 9, 2017, the Company’s $1,150,000 short-term note payable was converted into an aggregate of 165,865 shares of common stock and 9,399 shares of Series A Preferred Stock, eliminating the Company’s debt obligation. See Note 6. Original Issuance Discount The principal face value of the loan was $1,150,000 and was issued with an original issuance discount of $150,000 which resulted in aggregate proceeds of $1,000,000. The loan had a default interest rate of 15% per year and a maturity date of June 16, 2017. Prior to the conversion, the Company would have been required to repay the principal amount of the loan following the Company’s receipt of any financing in aggregate of $1,650,000 within six months from the closing. Additionally, investors had the option to convert the $150,000 original issuance discount, which accreted over the life of the loan, and principal into future financing or be paid back in cash. The note was also presented net of the issuance costs of $5,000 which accreted over the life of the note, based on the effective interest method. Accretion expense for the year ended December 31, 2017 and 2016 was approximately $32,000 and $111,000, respectively.

Common Stock Warrants

Common Stock Warrants	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Common Stock Warrants	Note 9 – Common Stock Warrants Fair value measurement valuation techniques, to the extent possible, should maximize the use of observable inputs and minimize the use of unobservable inputs. The Company’s fair value measurements of all warrants are designated as Level 1 since all of the significant inputs are observable and quoted prices were available in an active market for the four comparative companies used for volatility. A summary of the Company’s warrant issuance activity and related information as of December 31, 2017 and 2016 is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding at 12/31/2015 1,974,783 $ 2.86 4.0 Issued 1,530,064 $ 1.34 4.2 Outstanding at 12/31/2016 3,504,847 $ 1.85 3.9 Issued 3,889,368 $ 1.37 4.2 Cancelled (200,000 ) $ 1.625 — Outstanding at 12/31/2017 7,194,215 $ 1.74 3.4 Exercisable at 12/31/2017 7,194,215 $ 1.74 3.4 The fair value of all warrants issued are determined by using the Black-Scholes-Merton valuation technique and were assigned based on the relative fair value of both the common stock and the warrants issued. The inputs used in the Black-Scholes-Merton valuation technique to value each of the warrants issued in 2017 as of their respective issue dates are as follows: Event Description Date MDVX Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Private Placement 2/8/17 $ 1.04 $ 1.50 $ 0.38 5 years 1.81 52.21 Private Placement 7/14/17 $ 0.91 $ 1.15 $ 0.36 5 years 1.87 51.79 The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Note 10 – Discontinued operations Effective December 7, 2016, the Company sold all Streamline related assets after the Board authorized management to seek buyers for Streamline in May 2016. The Company sought additional funds to complete the development and launch of the Company’s primary product, the DenerveX System, and the decision to sell the Streamline assets helped raise part of the necessary funds required for continuing operations of the Company in a non-dilutive manner to existing shareholders. The sale resulted in the immediate receipt of $500,000 in cash, and a $150,000 note receivable due to the Company on or before January 1, 2018. The $150,000 note receivable represents the non-contingent portion of the receivables due from the sale and it also represents the short-term receivable as of December 31, 2017. The Company subsequently received the short-term receivable on January 2, 2018. See Note 16. Recording the present value of the receivable at December 31, 2016 and recognizing the subsequent accretion expense over the one-year period ended December 31, 2017 led to an immaterial amount. The terms of the sale also required that f or each of the calendar years ending December 31, 2018 and December 31, 2019 (each such calendar year, a “Contingent Period”), a contingent payment in cash (each, a “Contingent Payment”) equal to five percent (5%) of the total net sales received by the acquiring party from the sale of “IV suspension system” products in excess of 100 units during each Contingent Period. Each such Contingent Payment is payable to the Company by the acquiring party by no later than March 31 st The results of the discontinued operations, which represents Streamline’s IV Suspension System (“ISS”), are as follows: Year Ended December 31, 2017 2016 Operating Expenses General and administrative $ 1,163 $ 218,444 Research and development — 59,418 Depreciation and amortization — 189,652 Disposal loss — 852,864 Impairment loss — 1,584,048 Total Operating Expenses 1,163 2,904,426 Operating Loss (1,163 ) (2,904,426 ) Other Expenses Interest expense — 9,983 Total Other Expenses — 9,983 Net Loss $ (1,163 ) $ (2,914,409 ) Cash flows from discontinued operations are as follows: Year Ended December 31, 2017 2016 Cash Flows used in Operating Activities $ (1,163 ) $ (452,592 ) Cash Flows provided by Investing Activities — 1,286 Cash Flows used in Financing Activities — — Net Cash Used in Discontinued Operations $ (1,163 ) $ (451,306 ) Amortization expense related to the discontinued intangible assets for the year ended December 31, 2017 and 2016 was approximately $0 and $190,000, respectively. The recognition of amortization expense related to the discontinued assets ceased in May 2016 when the Board of Directors authorized Management to seek buyers for Streamline. Depreciation expense amounted to $0 and $129, respectively, for the year ended December 31, 2017 and 2016.

Impairment of Intangible Assets

Impairment of Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment of Intangible Assets and Goodwill	Note 11 – Impairment of Intangible assets and Goodwill As discussed in Note 2, the Company reviews long-lived assets for impairment whenever events or changes in circumstances or occurrence of events suggest impairment exists in accordance with FASB ASC 360. The Board of Directors decision to seek buyers for Streamline, as discussed in Note 10, As a result of the impairment analysis, the Company determined the carrying value of the developed technology exceeded the calculated fair value. Consequently, the Company recognized a write-down of approximately $1,035,714 related to the developed technology in the quarter ended June 30, 2016. As a result of the impairment analysis, the Company also determined the carrying value of the trademark and goodwill exceeded the calculated fair value. Consequently, impairment losses of $6,455,645 and $548,334, respectively, were recognized in the quarter ended June 30, 2016 related to goodwill and the trademark.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Note 12 - Income Taxes The Company’s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. As of December 31, 2017, the Company has not incurred any interest or penalties relating to uncertain tax positions. The Company’s evaluation was performed for the tax years ending December 31, 2016, 2015 and 2014, which remain subject to examination by major tax jurisdictions as of December 31, 2017. The Company does not have any tax years that are no longer subject to U.S. federal, state, and local, or non-US income tax examinations. For the years ended December 31, 2017 and 2016, the Company has incurred net losses and, therefore, has no current income tax liability and recognized no income tax expense. The net deferred tax asset generated by these losses, which principally consist of start-up costs deferred for income tax purposes, is fully reserved as of December 31, 2017 and 2016 since it is more likely than not that the benefit will not be realized in future periods. A reconciliation of the statutory federal income tax expense (benefit) to the effective tax is as follows: 2017 2016 Statutory rate – federal 21.0 % 34.0 % State taxes, net of federal benefit 4.0 4.0 Income tax benefit 25.0 % 38.0 % Less valuation allowance (25.0 ) (38.0 ) Total 0.00 % 0.00 % Our financial statements contain certain deferred tax assets which have arisen primarily as a result of tax benefits associated with the loss before income taxes incurred, as well as net deferred income tax assets resulting from other temporary differences related to certain reserves and differences between book and tax depreciation and amortization. We record a valuation allowance against our net deferred tax assets when we determine that based on the weight of available evidence, it is more likely than not that our net deferred tax assets will not be realized. In our evaluation of the weight of available evidence, we considered recent reported losses as negative evidence which carried substantial weight. Therefore, we considered evidence related to the four sources of taxable income, to determine whether such positive evidence outweighed the negative evidence associated with the losses incurred. The positive evidence considered included: ● taxable income in prior carryback years, if carryback is permitted under the tax law; ● future reversals of existing taxable temporary differences; ● tax planning strategies; and ● future taxable income exclusive of reversing temporary differences and carryforwards. During fiscal 2017 and 2016, we weighed all available positive and negative evidence and concluded the weight of the negative evidence of a cumulative loss continued to outweigh the positive evidence. Based on the conclusions reached, we maintained a full valuation allowance during 2017 and 2016. Deferred tax assets and liabilities consist of the following at December 31: 2017 2016 Deferred Tax Assets: Start-up costs $ 5,566,520 $ 5,738,469 Share-based compensation 238,109 203,761 Total Deferred Tax Assets 5,804,629 5,942,230 Valuation Allowance (5,804,629 ) (5,942,230 ) Net Deferred Tax Asset $ — $ — The Company is required to file federal income tax returns and state income tax returns in the states of Florida, Georgia and Minnesota. There are no uncertain tax positions at December 31, 2017. The Company has not undergone any tax examinations since inception and is therefore not subject to examination by any applicable tax authorities.

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related-Party Transactions	Note 13 - Related-Party Transactions Royalty Agreement As further described in Note 5, the Company has a Contribution and Royalty Agreement with Dr. Haufe. During 2017, the Company incurred an aggregate of approximately $1,600 in expenses under both the royalty and co-development agreements, of which approximately $1,000 was included in accounts payable at December 31, 2017. No royalties were incurred in 2016. Co-Development Agreement As further described in Note 7, the Company has a Co-Development Agreement with Dr. Andrews. During 2017, the Company incurred an aggregate of approximately $1,600 in expenses under both the royalty and co-development agreements, of which approximately $1,000 was included in accounts payable at December 31, 2017. No co-developments expenses were incurred in 2016. Aviation Expense Periodically the Company may charter general aviation aircraft from TAG Aviation LLC (“TAG”), a company owned by Mr. Jarrett Gorlin. The Company believes that such aircraft charter is on terms no less favorable then it would receive from a third party. General aviation expenses paid to TAG was approximately $0 and $26,000, respectively, for the years ended December 31, 2017 and 2016. Operating Lease As described in Note 7, the Company pays TAG Aviation LLC, (“TAG”), a company owned by Mr. Gorlin, for month to month rental of office space at Dekalb-Peachtree Airport in Atlanta Georgia plus cost of utilities. Rent payments under this arrangement is $2,147 per month. Rent expense and utilities cost paid to TAG Aviation amounted to approximately $34,600 and $30,400, respectively, for the years ended December 31, 2017 and 2016. Consulting Expense As described in Note 7, the Company paid $95,000 and $55,000, respectively, for the year ended December 31, 2017 and 2016 to a founding stockholder for business advisory services.

Research and Development

Research and Development	12 Months Ended
	Dec. 31, 2017
Research and Development [Abstract]
Research and Development	Note 14 - Research and Development Devicix Prototype Manufacturing Agreement In November 2013, the Company accepted a proposal from Devicix, a Minneapolis Minnesota based FDA registered contract medical device designer and developer, to develop a commercially viable prototype of its product that could be used to receive regulatory approval from the FDA and other international agencies for use on humans to relieve pain associated with Facet Joint Syndrome. The development work commenced in December 2013. The total estimated cost of this work was initially established at $960,000; however, the terms of the proposal allow either the Company or the manufacturer to cancel the development work with 10 days’ notice. During 2017, the Company incurred approximately $302,000 of expense under this agreement, with approximately $7,000 of the amount in payables at December 31, 2017. During 2016, the Company incurred approximately $481,000 of expense under this agreement, with approximately $63,000 of the amount in payables at December 31, 2016. Through December 31, 2017 and 2016, we have paid approximately $1,849,000 and $1,547,000, respectively, to Devicix under this agreement. The agreement with Devicix is now complete following the commercial launch of the DenerveX System. DenerveX Generator Manufacturing Agreement The DenerveX device requires a custom electrocautery generator for power. As described in Note 7, in November 2014, the Company contracted with Bovie to customize one of their existing electrocautery generators for use with DenerveX Device, and then manufacture that unit on a commercial basis once regulatory approval for the DenerveX was obtained. The Bovie agreement required a base $295,000 development fee to customize the unit, plus additional amounts if further customization was deemed necessary beyond predetermined estimates. The Company paid approximately $33,000 and $102,000, respectively, for the years ended December 31, 2017 and 2016. Through December 31, 2017 and 2016, we have paid approximately $422,000 and $389,000, respectively, to Bovie related to this agreement. The agreement with Bovie is now complete following the commercial launch of the DenerveX System. Nortech Manufacturing Agreement In November 2014, we selected Nortech Systems Inc. (“Nortech”), a Minneapolis, Minnesota based FDA registered contract manufacturer, to produce 315 DenerveX devices from the prototype supplied by Devicix for use in final development and clinical trials. The agreement with Nortech includes agreed upon per unit prices for delivery of the devices. Actual work on development of the final units began in November 2014. During 2017, the Company incurred approximately $146,000 of expense under this agreement, with approximately $40,000 of the amount in payables at December 31, 2017. During 2016, the Company incurred approximately $455,000 of expense under this agreement, with approximately $61,000 of the amount in payables at December 31, 2016. From inception through December 31, 2017 and 2016, we have paid approximately $890,000 and $744,000, respectively, to Nortech under the agreement. The agreement with Nortech is now complete following the commercial launch of the DenerveX System.

Liquidity, Going Concern and Ma

Liquidity, Going Concern and Management's Plans	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity, Going Concern and Management's Plans	Note 15 – Liquidity, Going Concern and Management’s Plans The Company incurred net losses of approximately $6,456,000 and $16,277,000 for the years ended December 31, 2017 and 2016, respectively. The Company will continue to incur losses until such time as it can sell a sufficient enough volume of the DenerveX System with margins sufficient to offset expenses. To date, the Company’s primary source of funds has been from the issuance of debt and equity. As discussed in Note 6, in February and July 2017, the Company obtained approximately $2,618,000 and $2,469,000, respectively, net of fees, in private equity financings. The Company will require additional cash in 2018 and is exploring other fundraising options. No assurances can be provided regarding the success of such efforts. Furthermore, if the Company is unable to raise sufficient financing in 2018, it could be required to undertake initiatives to conserve its capital resources, including delaying or suspending the launch of its product outside the United States and seeking FDA approval to sell its product in the United States. Delaying or suspending these initiatives would raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amounts of its assets or liabilities that might be necessary should the Company be unable to continue as a going concern.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 16 - Subsequent Events On January 2, 2018, the Company received the $150,000 short-term receivable from the sale of Streamline. See Note 10. On January 31, 2018, the Company issued a 5% convertible debenture in exchange for $100,000. The debenture accrues interest at 5% per annum. Principal and interest are due on January 30, 2019. The denture is convertible at the option of the holder into shares of the Company’s common stock at a conversion rate equivalent to 85% of the average closing price of the Company’s common stock for the 20 days preceding the conversion. On February 2, 2018, the Company received a resignation letter from Mr. Patrick Kullmann from his position as Chief Operating Officer of the Company. There were no disagreements between Mr. Kullmann and the Company. Mr. Kullmann will continue to work with the Company in an advisory capacity through July 31, 2018. On February 26, 2018, the Company entered into a securities purchase agreement with selected accredited investors whereby the Company sold an aggregate of 770,000 shares of common stock and 385,000 warrants to purchase common stock. The offering resulted in $308,000 in gross proceeds to the Company. The warrants have a five-year term commencing six months from issuance with an exercise price of $0.75. The shares were sold at $0.40 per share. On March 26, 2018 the Company issued a promissory note to Steve Gorlin, father of Jarrett Gorlin, the Company’s CEO, for the principal amount of $200,000, plus interest, at a rate of five percent per year. The outstanding principal and all accrued but unpaid interest is due on April 30, 2018. The Company issued warrants to purchase an aggregate of 133,333 shares of common stock par value $.001 per share in conjunction with the promissory note. Each warrant has an exercise price of $0.75 and is exercisable for a period of five years commencing from the date of issuance.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation And Principles of Consolidation The accompanying consolidated financial statements include the accounts of MedoveX Corp., its wholly-owned subsidiary, Debride, as well as its wholly owned subsidiary, Streamline Inc. (“Streamline”). All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates In preparing the financial statements, generally accepted accounting principles in the United States (“U.S. GAAP”) requires disclosure regarding estimates and assumptions used by management that affect the amounts reported in financial statements and accompanying notes. Actual results could differ from those estimates.
Cash	Cash The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s cash balances at December 31, 2017 and 2016 consists of funds deposited in checking accounts with commercial banks.
Accounts Receivable, Sales Returns, Discounts and Allowances	Accounts Receivable, Sales Returns, Discounts and Allowances Accounts receivable primarily represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized. The allowance is estimated for trade accounts receivable based on the expected collectability of accounts receivable after considering the Company’s historical collection experience and the length of time an account is outstanding. The adequacy of this allowance is reviewed each reporting period and adjusted as necessary. As the Company only commenced sales in July 2017, all outstanding trade receivables were deemed collectable, thus, no allowance for doubtful accounts was recorded at December 31, 2017 and 2016.
Other Receivables	Other Receivables Other receivables include input and importation value added tax (VAT) paid by the Company for conducting business in the European Union (“EU”) and for importing goods from outside the EU.
Inventory	Inventory Inventories consist of only finished goods and are valued at the lower of cost or net realizable value, using the first-in, first-out (FIFO) method.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to five years. Repairs and maintenance are expensed as incurred. Improvements and betterments, which extend the lives of the assets, are capitalized.
Leases	Leases The Company recognizes rent expense on a straight-line basis over the term of the lease. The lease term commences on the date the Company takes possession of or controls the physical use of the property. Deferred rent is included in non-current liabilities on the balance sheet.
Revenue Recognition	Revenue Recognition The Company has elected to early adopt Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers. Under ASC 606, the Company applies a new 5-step revenue recognition process as promulgated, the core principle of which necessitates companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. Identify the contract with the customer Medovex has two types of customers: distributors, and individual hospitals and practitioners. Distributors: We currently have distribution agreements with distributors located in Italy, Austria, Colombia, Scandinavia, Brazil, Israel, Australia, Turkey, Spain, Switzerland, Chile, Taiwan, Poland, Slovakia, the Czech Republic and the United Kingdom. For each distributor, a standardized distribution agreement is executed and is the definitive contract between the Company and the customer. Each distribution agreement details the pricing, order placement, stocking requirements, terms of payment, and shipping terms under which the DenerveX System will be shipped to the distributor. The distributor places orders for additional product, but all these orders are subject to the terms of the Distribution Agreement. Direct Customers: In Germany, all our customers are direct hospitals and individual practitioners. Sales in Germany are solicited by and placed with third party contractors on behalf of Medovex. Medovex has sales agreements with each third party sales representative selling the DenerveX System. Each sales agreement details the price at which the DenerveX System must be sold to the customer. A purchase order from the customer is required before the Company will ship product to the customer. This purchase order contains all the terms and conditions of the sale and is considered the definitive contract for this type of sale. Identify the performance obligation in the contract Our stocking distributors, who sell the DenerveX System to their customers or sub-distributors, contractually take title to the products and assume all risks of ownership at the time of shipment. The Company has no further obligations once the product is shipped. Our stocking distributors are obligated to pay us the contractually agreed upon invoice price within specified terms regardless of when, if ever, they sell the products. Since no right of return exists, the product is not considered consigned inventory. For direct sales to hospitals and practitioners in Germany, the obligation is met when the product is shipped. Our direct customers do not have any contractual rights of return or exchange other than for defective product or shipping error. Determine the transaction price DenerveX Kit: The DenerveX kit consists of one (1) Denervex handheld device, one (1) K-Wire, one (1) dilator, one (1) tissue stabilizer, (1) one portal tube and one (1) portal driver. The product is marketed as a disposable, single-use kit which includes all of the components packaged together. The transaction price for the DenerveX Kit is specifically outlined in the standardized distribution agreements for all distributors at a price of $492.50 per kit (each). The standardized distribution agreements also contain provisions for the purchase of demo-units at a transaction price of $246.25 per kit (each). The sales transaction price for one (1) DenerveX Kit is stated in US dollars for all distribution customers. The transaction price for the DenerveX Kit is specifically outlined in the standardized sales rep agreements for all sales contractors at a price of €1,100 per kit (each). The sales price for one (1) DenerveX Kit is stated in euros for all German sales. Pro-40 Generators: The DenerveX device requires a custom generator for power and cannot be used for any other purpose. For each initial order of the DenerveX Kit, a generator is provided to each customer at no charge. The Company does not recognize any revenue for the no-charge generator units. The units are removed from inventory and recognized as a cost of sales at the time of shipment. Customers may order demo generators, however, the Company charges for these units. The transaction price for the demo generators is specifically outlined in the standardized distribution agreement for all distributors at a price of $2,500 per unit. Allocate the transaction price In the Company’s case, 100% of the transaction price is recorded as revenue. Recognize revenue when or as the entity satisfies a performance obligation Revenue recognition occurs at the time product is shipped, FOB shipping, to all customers from the third-party distribution warehouse located in Berlin, Germany. For Medovex, this is considered the point at which the customer gains control of the Denervex device and there are no remaining material performance obligations. If something abnormal were to happen to the product in transit, the matter would be handles with the carrier, however, the sale would remain intact.
Research and Development	Research and Development Research and development costs are expensed as incurred.
Advertising	Advertising The Company expenses all sales and marketing costs as incurred. For the years ended December 31, 2017 and 2016, advertising costs were approximately $332,000 and $224,000, respectively.
Translation of Foreign Currencies	Translation of Foreign Currencies The Company’s revenues and expenses transacted in foreign currencies are translated as they occur at exchange rates in effect at the time of each transaction. Realized gains and losses on foreign currency transactions are recorded as a component of other income or expense, net on the Company’s consolidated statements of operations. As the Company commenced sales of the DenerveX System in July 2017, the Company recorded an immaterial amount in foreign currency exchange for the year ended December 31, 2017. Assets and liabilities of the Company denominated in foreign currencies are translated at the exchange rate in effect as of the balance sheet date and are recorded as a separate component of accumulated other comprehensive income or loss in the shareholders’ equity section of the Company’s consolidated balance sheet. The Company recorded an immaterial amount in unrealized foreign currency translation as of December 31, 2017, as such, we did not present as a separate component of accumulated other comprehensive income in the shareholders’ equity section of the Company’s consolidated balance sheet.
Income Taxes	Income Taxes The Company uses the liability method of accounting for income taxes, which requires recognition of temporary differences between financial statement and income tax bases of assets and liabilities, measured by enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets when necessary.
Stock-based Compensation	Stock-Based Compensation The Company maintains a stock option incentive plan and accounts for stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation
Loss Per Share	Loss per Share Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti- dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share: 7,194,215 warrants and 1,314,059 common stock options outstanding were considered anti-dilutive and excluded for the years presented.
Discontinued Operations	Discontinued Operations As more fully described in Note 10, in May 2016, management was authorized to locate a buyer for Streamline Inc., the Company’s wholly owned subsidiary acquired in March 2015, by the Board of Directors. Streamline’s results of operations have been classified as discontinued operations for all periods presented.
Fair Value Measurements	Fair Value Measurements We measure certain non-financial assets at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group; and applying accounting for business combinations. We use the fair value measurement framework to value these assets and report the fair values in the periods in which they are recorded or written down. The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels. These levels from highest to lowest priority are as follows: ● Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities; ● Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data; and ● Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available. The determination of fair value and the assessment of a measurement’s placement within the hierarchy requires judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. We may also engage external advisors to assist us in determining fair value, as appropriate. Although we believe that the recorded fair value of our financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.
Goodwill and Impairment of Long-lived Assets	Goodwill And Impairment of Long-Lived Assets Goodwill is the excess of the purchase price over the fair value of net assets of acquired businesses. Goodwill is tested for impairment annually or whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The test for impairment requires us to make several estimates about fair value. Our estimates associated with the goodwill impairment test are considered critical due to the amount of goodwill recorded on our consolidated balance sheets and the judgment required in determining fair value. Other intangible assets include trademarks and purchased technology. Intangible assets with a definite life are amortized on a straight-line basis, as appropriate, with estimated useful lives ranging from five to seven years, and are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. Definite-lived intangible assets are tested for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consist solely of cash. At times throughout the year, the Company may maintain certain US bank account balances in excess of FDIC insured limits. The Company may also maintain German bank account balances in excess of Germany’s deposit guarantee regulations within the framework of the German Banks’ Compensation Scheme. At December 31, 2017, the Company did not have cash deposits that exceeded federally insured deposit limits in the US or Germany. At December 31, 2016, the Company had only US cash deposits that exceeded federally insured deposit limits. The Company believes that its funds are deposited in high credit quality financial institutions. The Company has not experienced any losses in such accounts to date and believes it is not exposed to any significant credit risk associated with its cash deposits.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements The Company considers the applicability and impact of all ASUs issued, both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company adopted the amendments of ASU 2014-09 effective quarter ended September 30, 2017. The adoption of this standard did not have a material impact on our consolidated financial statements. In July 2015, the FASB issued ASU 2015-11, “Inventory (Topic 330),” which requires inventory measured using any method other than last-in, first-out or the retail inventory method to be subsequently measured at the lower of cost or net realizable value, rather than the lower of cost or market. ASU No. 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those years. The Company adopted the amendments of ASU 2015-11 effective January 1, 2017. The adoption of this standard did not have a material impact on our consolidated financial statements. In November 2015, FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consisted of the following items as of December 31, 2017, and December 31, 2016: December 31, 2017 December 31, 2016 Split Return Electrodes $ 1,868 $ — Denervex device 111,596 — Pro-40 generator 181,250 — Total $ 294,714 $ —

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following: Useful Life December 31, 2017 December 31, 2016 Furniture and fixtures 5 years $ 67,777 $ 65,987 Computers and software 3 years 31,738 19,928 Leasehold improvements 5 years 35,676 32,593 135,191 118,508 Less accumulated depreciation (48,018 ) (20,918 ) Total $ 87,173 $ 97,590

Equity Transactions (Tables)

Equity Transactions (Tables)	12 Months Ended
	Dec. 31, 2017
Nonmonetary Transactions [Abstract]
Significant Assumptions Used to Estimate the Fair Value of the Equity Awards	The significant assumptions used to estimate the fair value of the equity awards granted are; Grant date February 3 March 28 Fair value of options granted $ 0.5775 $ 0.6856 Expected term (years) 6 6 Risk-free interest rate 2.10 % 2.11 % Volatility 52.31 % 51.86 % Dividend yield None None
Summary of Stock Option Activity	A summary of the Company’s share-based compensation activity and related information is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Term (Years) Outstanding at 12/31/2015 380,000 $ 3.95 9.1 Granted 744,900 $ 1.24 9.52 Exercised — — — Cancelled — — — Outstanding at 12/31/2016 1,124,900 $ 2.15 9.0 Granted 189,159 $ 1.17 9.10 Exercised — — — Cancelled — — — Outstanding at 12/31/2017 1,314,059 $ 2.01 8.19 Exercisable at 12/31/2017 954,740 $ 2.08 8.13

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2017
Office Space [Member]
Schedule of Operating Leases	For the year ended December 31, 2018 21,000 $ 21,000
Equiment [Member]
Schedule of Operating Leases	For the year ended : December 31, 2018 800 $ 800

Short Term Liabilities (Tables)

Short Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Future Payments Related to the Promissory Notes	Expected future payments related to the promissory notes as of December 31, 2017, are approximately as follows: For the year ended 2018 64,000 2019 45,000 $ 109,000

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Summary of Warrant Activity	A summary of the Company’s warrant issuance activity and related information as of December 31, 2017 and 2016 is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding at 12/31/2015 1,974,783 $ 2.86 4.0 Issued 1,530,064 $ 1.34 4.2 Outstanding at 12/31/2016 3,504,847 $ 1.85 3.9 Issued 3,889,368 $ 1.37 4.2 Cancelled (200,000 ) $ 1.625 — Outstanding at 12/31/2017 7,194,215 $ 1.74 3.4 Exercisable at 12/31/2017 7,194,215 $ 1.74 3.4
Schedule of Assumptions for Warrants	The inputs used in the Black-Scholes-Merton valuation technique to value each of the warrants issued in 2017 as of their respective issue dates are as follows: Event Description Date MDVX Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Private Placement 2/8/17 $ 1.04 $ 1.50 $ 0.38 5 years 1.81 52.21 Private Placement 7/14/17 $ 0.91 $ 1.15 $ 0.36 5 years 1.87 51.79

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Results of Discontinued Operations	The results of the discontinued operations, which represents Streamline’s IV Suspension System (“ISS”), are as follows: Year Ended December 31, 2017 2016 Operating Expenses General and administrative $ 1,163 $ 218,444 Research and development — 59,418 Depreciation and amortization — 189,652 Disposal loss — 852,864 Impairment loss — 1,584,048 Total Operating Expenses 1,163 2,904,426 Operating Loss (1,163 ) (2,904,426 ) Other Expenses Interest expense — 9,983 Total Other Expenses — 9,983 Net Loss $ (1,163 ) $ (2,914,409 )
Schedule of Cash Flows from Discontinued Operations	Cash flows from discontinued operations are as follows: Year Ended December 31, 2017 2016 Cash Flows used in Operating Activities $ (1,163 ) $ (452,592 ) Cash Flows provided by Investing Activities — 1,286 Cash Flows used in Financing Activities — — Net Cash Used in Discontinued Operations $ (1,163 ) $ (451,306 )

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	A reconciliation of the statutory federal income tax expense (benefit) to the effective tax is as follows: 2017 2016 Statutory rate – federal 21.0 % 34.0 % State taxes, net of federal benefit 4.0 4.0 Income tax benefit 25.0 % 38.0 % Less valuation allowance (25.0 ) (38.0 ) Total 0.00 % 0.00 %
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities consist of the following at December 31: 2017 2016 Deferred Tax Assets: Start-up costs $ 5,566,520 $ 5,738,469 Share-based compensation 238,109 203,761 Total Deferred Tax Assets 5,804,629 5,942,230 Valuation Allowance (5,804,629 ) (5,942,230 ) Net Deferred Tax Asset $ — $ —

Organization (Details Narrative

Organization (Details Narrative)	12 Months Ended
	Dec. 31, 2017
State of incorporation	Nevada
Date of incorporation	Jul. 30, 2013
Debride Inc. [Member]
State of incorporation	Florida
Date of incorporation	Oct. 1, 2012

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Details Narrative)	12 Months Ended
	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2017EUR (€)shares	Dec. 31, 2016USD ($)
Price per kit | $ / shares	$ 492.50
Advertising costs | $	$ 332,000		$ 224,000
Trademark [Member]
Estimated useful life	5 years	5 years
Purchased Technology [Member]
Estimated useful life	7 years	7 years
Warrant [Member]
Antidilutive securities excluded from computation of earnings per shares | shares	7,194,215	7,194,215
Common Stock [Member]
Antidilutive securities excluded from computation of earnings per shares | shares	1,314,059	1,314,059
DenerveX Kit [Member] | Euro [Member]
Sales contractors a price of kit | €		€ 1,100
Distribution Agreements [Member]
Price per kit | $ / shares	$ 246.25
Generators distributors a price | $	$ 2,500
Concentration risk, percentage	100.00%	100.00%
Minimum [Member]
Property plant and equipment useful life	3 years	3 years
Maximum [Member]
Property plant and equipment useful life	5 years	5 years

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Inventory	$ 294,714
Split Return Electrodes [Member]
Inventory	1,868
Denervex Device [Member]
Inventory	111,596
Pro-40 Generator [Member]
Inventory	$ 181,250

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 27,100	$ 11,267

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property and equipment	$ 135,191	$ 118,508
Less accumulated depreciation	(48,018)	(20,918)
Property and Equipment, net	87,173	97,590
Furniture and Fixtures [Member]
Property and equipment	$ 67,777	65,987
Useful Life	5 years
Computers and Software [Member]
Property and equipment	$ 31,738	19,928
Useful Life	3 years
Leasehold Improvements [Member]
Property and equipment	$ 35,676	$ 32,593
Useful Life	5 years

Patent Assignment and Contrib37

Patent Assignment and Contribution Agreements (Details Narrative) - USD ($)	Feb. 01, 2013	Dec. 31, 2017	Dec. 31, 2016
Royalty expire date		Sep. 6, 2030
Royalty and Co-Development Agreements [Member]
Royalty expenses		$ 1,600
Accounts payable		$ 1,000
Dr. Haufe [Member] | Royalty Agreement [Member]
Number of common stock shares issued	750,108
Revenue percentage	1.00%

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)	Aug. 17, 2017	Jul. 14, 2017	Apr. 21, 2017	Mar. 28, 2017	Feb. 09, 2017	Oct. 14, 2013	Oct. 31, 2017	Aug. 31, 2017	Jan. 31, 2017	Nov. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Oct. 30, 2017	Oct. 28, 2017	Jan. 17, 2017	Nov. 10, 2016
Common stock shares issued											21,163,013	14,855,181
Common stock par value											$ 0.001	$ 0.001
Shares issued price per share							$ 1.17		$ 1.38
Short term note payable converted into shares of common stock, value											$ 145,919
Short term note payable converted into shares of common stock, shares											200,000
Number of warrants cancelled											200,000
Closing price of share													$ 1.09		$ 1.16
Common stock issued fair value											$ 21,163	$ 14,855
Stock options authorized incentive plan											189,159
Compensation expense											$ 544,000	777,000
Non vested options outstanding											359,319
Unrecognized stock-based compensation											$ 184,000
Weighted average period											1 year 8 months 23 days
Fair value of vested share-based compensation											$ 486,000	$ 697,000
Number of aggregate shares issued for unpaid directors fees							115,389		173,912
2013 Stock Option Incentive Plan [Member]
Stock options authorized incentive plan														1,000,000		500,000
Stock options vested, percent											25.00%
2013 Stock Option Incentive Plan [Member] | Restricted Stock [Member]
Shares available for grant								300,000
Short-term Note Payable [Member]
Short term note payable converted into shares of common stock, value					$ 1,150,000
Short term note payable converted into shares of common stock, shares					165,865
Debt conversion into share price per share					$ 1.04
Number of warrants cancelled					200,000
Series A Preferred Stock [Member]
Short term note payable converted into shares of common stock, shares					9,399
Conversion of stock shares converted			5,252	4,147
Number of common stock shares issued for conversion			525,240	414,663
Common stock conversion price per share			$ 0.001	$ 0.001
Series A Preferred Stock [Member] | Short-term Note Payable [Member]
Short term note payable converted into shares of common stock, shares					9,399
Note Holders [Member] | Short-term Note Payable [Member]
Number of warrants issued to purchase common shares					200,000
Number of common stock shares issued in offering					200,000
Closing price of share					$ 1.04
Common stock issued fair value					$ 208,000
Board Members [Member]
Number of common stock shares authorized for issuance, value								$ 135,000		$ 240,000
Consultant [Member]
Number of common stock shares issued in offering											175,000
Shares available for grant											300,000
Stock options vested, percent											25.00%
Compensation expense											$ 81,000
Consultant [Member] | Grant 40% [Member]
Vested period	4 months
Consultant [Member] | Grant 35% [Member]
Vested period	1 year
Board of Directors [Member]
Number of common stock shares issued in offering											125,000
Shares available for grant											300,000
Stock options vested, percent											25.00%
Compensation expense											$ 34,000
Board of Directors [Member] | Grant 25% [Member]
Vested period	1 year
Board of Directors [Member] | Grant 50% [Member]
Vested period	2 years
Minimum [Member] | 2013 Stock Option Incentive Plan [Member]
Shares available for grant														1,650,000		1,150,000
Maximum [Member] | 2013 Stock Option Incentive Plan [Member]
Shares available for grant														2,650,000		1,650,000
Maximum [Member] | Employees, Consultants and Directors [Member] | 2013 Stock Option Incentive Plan [Member]
Plan option grant						1,150,000
Securities Purchase Agreement [Member] | Accredited Investors [Member]
Number of warrants issued to purchase common shares		1,478,022
Warrant initial exercise price		$ 1.15
Warrant exercisable period		5 years
Proceeds from private offering		$ 2,690,686
Number of common stock shares sold		2,956,043
Sale of stock price per share		$ 0.91
Placement agent collected fees related to offering		$ 188,000
Private Placement [Member] | Unit Purchase Agreement [Member]
Purchase price of capital units					$ 100,000
Common stock shares issued					96,154
Common stock par value					$ 0.001
Shares issued price per share					$ 1.04
Number of warrants issued to purchase common shares					48,077
Warrant initial exercise price					$ 1.50
Warrant exercisable period					5 years
Proceeds from private offering					$ 3,022,000
Number of common stock shares issued in offering					1,631,730
Offering fees					$ 350,000
Private Placement [Member] | Unit Purchase Agreement [Member] | Warrant [Member]
Number of warrants issued to purchase common shares					2,005,761
Private Placement [Member] | Unit Purchase Agreement [Member] | Series A Preferred Stock [Member]
Number of common stock shares issued in offering					12,740
Private Placement [Member] | Unit Purchase Agreement [Member] | Placement Agent [Member]
Number of warrants issued to purchase common shares					405,577
Warrant initial exercise price					$ 1.50
Private Placement [Member] | Unit Purchase Agreement [Member] | Minimum [Member] | Accredited Investors [Member]
Capital units, value					$ 3,000,000
Private Placement [Member] | Unit Purchase Agreement [Member] | Maximum [Member] | Accredited Investors [Member]
Capital units, value					$ 5,000,000

Equity Transactions - Significa

Equity Transactions - Significant Assumptions Used to Estimate the Fair Value of the Equity Awards (Details)	12 Months Ended
	Dec. 31, 2017$ / shares
Feb 03 2017 [Member]
Fair value of options granted	$ 0.5775
Expected term (years)	6 years
Risk-free interest rate	2.10%
Volatility	52.31%
Dividend yield	0.00%
March 28 2017 [Member]
Fair value of options granted	$ 0.6856
Expected term (years)	6 years
Risk-free interest rate	2.11%
Volatility	51.86%
Dividend yield	0.00%

Equity Transactions - Summary o

Equity Transactions - Summary of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Nonmonetary Transactions [Abstract]
Number of Options Outstanding, Beginning	1,124,900	380,000
Number of Options Granted	189,159	744,900
Number of Options Outstanding, Ending	1,314,059	1,124,900
Number of Options Outstanding, Exercisable	954,740
Weighted Average Exercise Price Outstanding, Beginning	$ 2.15	$ 3.95
Weighted Average Exercise Price Granted	1.17	1.24
Weighted Average Exercise Price Outstanding, Ending	2.01	$ 2.15
Weighted Average Exercise Price Outstanding, Exercisable	$ 2.08
Weighted Average Remaining Term, Outstanding	9 years	9 years 1 month 6 days
Weighted Average Remaining Term, Granted	9 years 1 month 6 days	9 years 6 months 7 days
Weighted Average Remaining Term, Outstanding	8 years 2 months 8 days	9 years
Weighted Average Remaining Term, Exercisable	8 years 1 month 16 days	0 years

Commitments (Details Narrative)

Commitments (Details Narrative)	Aug. 23, 2017USD ($)	Jul. 08, 2015	Jul. 31, 2017USD ($)	Jan. 31, 2017USD ($)	Sep. 30, 2013	Dec. 31, 2017USD ($)	Dec. 31, 2017EUR (€)	Dec. 31, 2016USD ($)
Rent/Lease expense						$ 35,000		$ 34,000
Agreement, term		3 years
Termination date	May 10, 2018
Pathway of development amount						295,000
Accounting monthly fees						95,000		55,000
Potential Mergers [Member]
Advisory services fees, amount	$ 75,000
Three Sales, Marketing, and Distribution Consultant [Member]
Payments for consulting services						238,000		85,000
Non-cancellable 36 Month Operating Lease Agreement [Member]
Rent/Lease expense						2,600		2,600
Consulting Agreement [Member]
Payments for consulting services						95,000		55,000
Advisory services fees, amount	$ 25,000
Consulting Agreement [Member] | Sales, Marketing, and Distribution Consultant [Member]
Payments for consulting services						66,000		10,000
Consulting Agreement [Member] | Three Sales, Marketing, and Distribution Consultant [Member]
Payments for consulting services						$ 33,000
Termination date						Apr. 30, 2019	Apr. 30, 2019
Consulting Agreement [Member] | Three Sales, Marketing, and Distribution Consultant [Member] | EURO [Member]
Payments for consulting services | €							€ 27,500
Consulting Agreement [Member] | Minimum [Member]
Payments for consulting services				$ 5,000
Consulting Agreement [Member] | Minimum [Member] | Sales, Marketing, and Distribution Consultant [Member]
Payments for consulting services			$ 5,000
Consulting Agreement [Member] | Maximum [Member]
Payments for consulting services				$ 10,000
Consulting Agreement [Member] | Maximum [Member] | Sales, Marketing, and Distribution Consultant [Member]
Payments for consulting services			$ 7,000
Employment Agreements [Member] | Six Executive Officers [Member]
Agreement, term						3 years	3 years
Compensation						$ 1,064,000		984,000
Co-Development Agreement [Member]
Agreement, description					In exchange for these services the Company is obligated to pay Dr. Andrews a royalty of 2% of revenues earned from applicable product sales over a period of 5 years. If Dr. Andrews is listed as inventor of any Improvement Patent on the DenerveX device during the 5-year term, he would continue to receive a 1% royalty after the 2% royalty expires for the duration of the effectiveness of the Improvement Patent.
Generator Development Agreement [Member]
Payment to Bovie						295,000
Generator Development Agreement [Member] | Pro-40 Electrocautery Generator [Member]
Payment to Bovie						33,200		102,400
Generator Development Agreement [Member] | Production Services [Member]
Payment to Bovie								422,000
Distribution Center and Logistic Services Agreement [Member]
Accounting monthly fees						75,700		3,500
Distribution Center and Logistic Services Agreement [Member] | EURO [Member]
Accounting monthly fees | €							€ 2,900
Distribution Center and Logistic Services Agreement [Member] | Minimum [Member]
Accounting monthly fees						2,300
Distribution Center and Logistic Services Agreement [Member] | Minimum [Member] | EURO [Member]
Accounting monthly fees | €							1,900
Distribution Center and Logistic Services Agreement [Member] | Maximum [Member]
Accounting monthly fees						8,300
Distribution Center and Logistic Services Agreement [Member] | Maximum [Member] | EURO [Member]
Accounting monthly fees | €							€ 6,900
TAG Aviation [Member]
Rent/Lease expense						34,600		$ 30,400
Operating Leases [Member]
Rent/Lease expense						$ 2,147

Commitments - Schedule of Opera

Commitments - Schedule of Operating Leases (Details)	Dec. 31, 2017USD ($)
Office Space [Member]
December 31, 2018	$ 21,000
Total	21,000
Equiment [Member]
December 31, 2018	800
Total	$ 800

Short Term Liabilities (Details

Short Term Liabilities (Details Narrative) - USD ($)	Feb. 09, 2017	Mar. 25, 2015	Dec. 31, 2017	Dec. 31, 2016	Sep. 13, 2016	Mar. 31, 2015
Promissory note face amount			$ 104,000	$ 165,000
Debt instrument interest rate			15.00%
Debt instrument maturity date			Jun. 16, 2017
Debt interest expense			$ 7,000	10,000
Unpaid accrued interest			$ 69,222	69,222
Short-term note payable	$ 1,150,000
Debt converted into shares			200,000
Original issue discount			$ 150,000
Proceeds from debt			1,000,000
Repayments of debt			1,650,000
Debt issuance cost			5,000
Accretion expense			32,000	111,000
Common Stock [Member]
Debt converted into shares	165,865
Series A Preferred Stock [Member]
Debt converted into shares	9,399
Board of Directors [Member]
Promissory note face amount					$ 1,150,000
Investor [Member]
Original issue discount			150,000
Promissory Note One [Member]
Promissory note face amount						$ 135,000
Promissory Note Two [Member]
Promissory note face amount						$ 125,000
Two Promissory Note [Member]
Promissory notes		$ 5,700	$ 5,700
Debt instrument interest rate		5.00%	5.00%
Debt instrument maturity date		Aug. 1, 2019	Aug. 1, 2019
Unpaid accrued interest			$ 69,000	$ 69,000
Finance Agreement [Member]
Insurance premium finance payments due			$ 24,000
Insurance premium finance annual percentage			5.98%
Promissory notes			$ 68,000

Short Term Liabilities - Future

Short Term Liabilities - Future Payments Related to the Promissory Notes (Details)	Dec. 31, 2017USD ($)
Debt Disclosure [Abstract]
2,018	$ 64,000
2,019	45,000
Total	$ 109,000

Common Stock Warrants - Summary

Common Stock Warrants - Summary of Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Shares, Outstanding, beginning	3,504,847	1,974,783
Shares, Issued	3,889,368	1,530,064
Shares, Cancelled	(200,000)
Shares, Outstanding, ending	7,194,215	3,504,847
Shares, Exercisable, ending	7,194,215
Weighted Average Exercise Price, Outstanding, beginning	$ 1.85	$ 2.86
Weighted Average Exercise Price, Issued	1.37	1.34
Weighted Average Exercise Price, Cancelled	1.625
Weighted Average Exercise Price, Outstanding, ending	$ 1.74	$ 1.85
Weighted Average Exercise Price, Exercisable, ending	1.74
Weighted Average Remaining Contractual Life, Outstanding, beginning	3 years 10 months 25 days	4 years
Weighted Average Remaining Contractual Life, Issued	4 years 2 months 12 days	4 years 2 months 12 days
Weighted Average Remaining Contractual Life, Outstanding, ending	3 years 4 months 24 days	3 years 10 months 25 days
Weighted Average Remaining Contractual Life, Exercisable, Ending	3 years 4 months 24 days

Common Stock Warrants - Schedul

Common Stock Warrants - Schedule of Assumptions for Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Oct. 30, 2017	Jan. 17, 2017
MDVX Stock Price		$ 1.09	$ 1.16
Private Placement 2/8/17 [Member]
MDVX Stock Price	$ 1.04
Exercise Price of Warrant	1.50
Grant Date Fair Value	$ 0.38
Life of Warrant	5 years
Risk Free Rate of Return (%)	1.81%
Annualized Volatility Rate (%)	52.21%
Private Placement 7/14/17 [Member]
MDVX Stock Price	$ 0.91
Exercise Price of Warrant	1.15
Grant Date Fair Value	$ 0.36
Life of Warrant	5 years
Risk Free Rate of Return (%)	1.87%
Annualized Volatility Rate (%)	51.79%

Discontinued Operations (Detail

Discontinued Operations (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Proceeds for sale assets		$ 500,000
Note receivable from disposition of Streamline		150,000
Short-term receivable	150,000
Amortization expense		189,522
Depreciation	0	$ 129
Maximum [Member]
Aggregate value of contingent payments	$ 850,000

Discontinued Operations - Sched

Discontinued Operations - Schedule of Results of Discontinued Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
General and administrative	$ 1,163	$ 218,444
Research and development		59,418
Depreciation and amortization		189,652
Disposal loss		852,864
Impairment loss		(1,584,048)
Total Operating Expenses	1,163	2,904,426
Operating Loss	(1,163)	(2,904,426)
Interest expense		9,983
Total Other Expenses		9,983
Net Loss	$ (1,163)	$ (2,914,409)

Discontinued Operations - Sch49

Discontinued Operations - Schedule of Cash Flows from Discontinued Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Cash Flows used in Operating Activities	$ (1,163)	$ (452,592)
Cash Flows used in Investing Activities		1,286
Cash Flows used in Financing Activities
Net Cash Used in Discontinued Operations	$ (1,163)	$ (451,306)

Impairment of Intangible Asse50

Impairment of Intangible Assets and Goodwill (Details Narrative)	3 Months Ended
	Jun. 30, 2016USD ($)
Goodwill [Member]
Impairment of intangible assets	$ 6,455,645
Trademarks [Member]
Impairment of intangible assets	548,334
Developed Technology [Member]
Written down of impairment of intangible assets	$ 1,035,714

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Statutory rate - federal	21.00%	34.00%
State taxes, net of federal benefit	4.00%	4.00%
Income tax benefit	25.00%	38.00%
Less valuation allowance	(25.00%)	(38.00%)
Total	0.00%	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Start-up costs	$ 5,566,520	$ 5,738,469
Share-based compensation	238,109	203,761
Total Deferred Tax Assets	5,804,629	5,942,230
Valuation Allowance	(5,804,629)	(5,942,230)
Net Deferred Tax Asset

Related-Party Transactions (Det

Related-Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Rent expense	$ 35,000	$ 34,000
Consulting expense	95,000	55,000
TAG Aviation LLC [Member]
Aviation expense	0	26,000
Rent expense	34,600	30,400
TAG Aviation LLC [Member] | Operating Lease [Member]
Rent expense	2,147
Royalty Agreement [Member] | Dr. Haufe [Member]
Royalty payable	1,600
Accounts payable	1,000
Co-Development Agreement [Member] | Dr. Andrews [Member]
Royalty payable	1,600
Accounts payable	$ 1,000

Research and Development (Detai

Research and Development (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Contract cost	$ 960,000
Research and Development expenses	491,076	$ 1,126,535
Devicix Prototype Manufacturing Agreement [Member]
Research and Development expenses	302,000	481,000
Accounts payable	7,000	63,000
Denervex Generator Manufacturing Agreement [Member]
Research and Development expenses	33,000	102,000
Development fees	295,000
Nortech Manufacturing Agreement [Member]
Research and Development expenses	146,000	455,000
Accounts payable	40,000	61,000
Nortech [Member]
Research and Development expenses	890,000	744,000
Devicix [Member]
Research and Development expenses	1,849,000	1,547,000
Bovie [Member] | Denervex Generator Manufacturing Agreement [Member]
Payment to Bovie	$ 422,000	$ 389,000

Liquidity, Going Concern and 55

Liquidity, Going Concern and Management's Plans (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Jul. 31, 2017	Feb. 28, 2017	Dec. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss			$ 6,456,477	$ 16,227,484
Proceeds from private equity financings	$ 2,469,000	$ 2,618,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 26, 2018	Feb. 26, 2018	Jan. 31, 2018	Oct. 31, 2017	Jan. 31, 2017	Dec. 31, 2017	Jan. 02, 2018	Dec. 31, 2016
Short-term receivables						$ 150,000
Convertible debt, percentage						15.00%
Principal and interest due date						Jun. 16, 2017
Aggregate shares issued to purchase common stock				115,389	173,912
Proceeds from issuance of debt						$ 1,000,000
Shares issued price per share				$ 1.17	$ 1.38
Long term receivable								150,000
Promissory note						$ 104,000		$ 165,000
Subsequent Event [Member]
Short-term receivables							$ 150,000
Convertible debt, percentage	5.00%
Principal and interest due date	Apr. 30, 2018
Warrant, exercise price	$ 0.75
Shares issued price per share	$ .001
Promissory note	$ 200,000
Warrants to purchase shares of common stock	133,333
Subsequent Event [Member] | Accredited Investors [Member]
Proceeds from issuance of debt		$ 308,000
Term of warrants		5 years
Warrant, exercise price		$ 0.75
Shares issued price per share		$ 0.40
Subsequent Event [Member] | Accredited Investors [Member] | Common Stock [Member]
Aggregate shares issued to purchase common stock		770,000
Subsequent Event [Member] | Accredited Investors [Member] | Warrant [Member]
Aggregate shares issued to purchase common stock		385,000
Subsequent Event [Member] | Convertible Debenture [Member]
Convertible debt, percentage			5.00%
Proceeds from convertible debt			$ 100,000
Subsequent Event [Member] | Debenture [Member]
Interest accrued			5.00%
Principal and interest due date			Jan. 30, 2019
Conversion of common stock, percentage			85.00%